Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Daiichi Sankyo, Inc. et al. Post grant review
Case Number:
Case Type:
PGR
Status:
Trial Instituted
Petitioner:
Daiichi Sankyo, Inc. et al.
Patent Owner:
Tech Center:
-
January 17, 2024
PTAB Nixes Seagen Cancer Drug IP After Daiichi Verdict
The Patent Trial and Appeal Board has said Daiichi Sankyo was able to show that the challenged claims of a Seagen cancer drug patent, which a Texas federal jury found Daiichi infringed in a $42 million verdict in 2022, were invalid.
-
August 17, 2023
IP Forecast: Pinterest Looks To Defend DMCA Win At 9th Circ.
Pinterest heads to the Ninth Circuit next week to defend a lower court ruling that allowed the company to use the Digital Millennium Copyright Act to shield itself from copyright litigation over how it markets images that users upload to the social media site. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.
-
February 15, 2023
In 3rd Reversal, PTAB Will Eye Seagen Patent In $42M Case
Reversing itself for the third time, the Patent Trial and Appeal Board has agreed to review a Seagen cancer drug patent, finding that Daiichi Sankyo, which a Texas jury told to pay $42 million for infringing the patent, presented "compelling evidence" that it is invalid.
-
July 18, 2022
Seagen Gets PGR Nixed Under Fintiv In Rehearing Decision
Seagen Inc. has persuaded the Patent Trial and Appeal Board on rehearing to deny a challenge from Daiichi Sankyo Inc. and AstraZeneca Pharmaceuticals LP to its cancer antibody patent, with the board saying the post-grant review is no longer warranted under the controversial Fintiv precedent.
-
April 08, 2022
PTAB To Review Cancer Antibody IP That Drew $41.8M Verdict
The Patent Trial and Appeal Board has agreed to review a Seagen Inc. antibody patent after the board previously used its discretion to reject two challenges from Daiichi Sankyo Inc. and AstraZeneca while a Texas federal jury on Friday found Daiichi willfully infringed the patent to the tune of $41.8 million.
-
June 25, 2021
PTAB Won't Hear 2 Daiichi PGRs On Cancer Antibody IP
The Patent Trial and Appeal Board said it won't review a Seagen Inc. cancer drug delivery patent being challenged by Daiichi Sankyo Inc. and AstraZeneca, noting that the drugmakers offered few assurances that they won't pursue the same invalidity arguments in parallel district court litigation.